<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39053954</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Randomised, double-blind, placebo-controlled study evaluating the effect of allopurinol on the risk of cardiovascular events in patients with high and very high cardiovascular risk, including the presence of long-COVID-19 syndrome: the ALL-VASCOR study protocol.</ArticleTitle><Pagination><StartPage>e075741</StartPage><MedlinePgn>e075741</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e075741</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2023-075741</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The randomised, double-blind, placebo-controlled study evaluating the effect of allopurinol on the risk of cardiovascular events in patients with high and very high cardiovascular risk, including the presence of long-COVID-19 syndrome (ALL-VASCOR) study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk excluding ischaemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of mortality.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">The ALL-VASCOR study is a randomised, double-blind, placebo-controlled, multicentre trial that examines the effect of allopurinol therapy (200-500&#x2009;mg of allopurinol daily) versus an equivalent dose of placebo on the risk of cardiovascular events in 1116 patients aged 40-70 with serum uric acid levels above 5&#x2009;mg/dL at high and very high risk of cardiovascular disease. The ALL-VASCOR study will also assess the occurrence of long-COVID-19 syndrome. The study will measure primary and secondary as well as additional endpoints and the planned intervention will end on 31 July 2028 unless advised otherwise by the Safe Monitoring Board or other applicable authorities. Participant recruitment is planned to begin in March 2024 in Poland.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">The study was ethically approved by the Bioethics Committee of Poznan University of Medical Sciences (No 03/23, 12 January 2023). The results are expected after 2028 and will be disseminated in peer-reviewed journals and at international conferences.</AbstractText><AbstractText Label="PROTOCOL VERSION NUMBER" NlmCategory="UNASSIGNED">01-15 November 2022.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">EudraCT: 2022-003573-32, 27 October 2022, ClinicalTrials: NCT05943821, 13 July 2023.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewandowska</LastName><ForeName>Katarzyna</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6385-886X</Identifier><AffiliationInfo><Affiliation>Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland katarzyna.lewandowska@usk.poznan.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipski</LastName><ForeName>Dawid</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uruski</LastName><ForeName>Pawe&#x142;</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narkiewicz</LastName><ForeName>Krzysztof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Januszewicz</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prejbisz</LastName><ForeName>Aleksander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Cardiovascular Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajzer</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>First Department of Cardiology, Interventional Electrocardiology and Arterial Hypertension, Jagiellonian University Medical College, Krakow, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wi&#x119;cek</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tykarski</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hypertensiology, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05943821</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>63CZ7GJN5I</RegistryNumber><NameOfSubstance UI="D000493">Allopurinol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000493" MajorTopicYN="Y">Allopurinol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082742" MajorTopicYN="N">Heart Disease Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult cardiology</Keyword><Keyword MajorTopicYN="N">cardiology</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>26</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>25</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39053954</ArticleId><ArticleId IdType="pmc">PMC11284933</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2023-075741</ArticleId><ArticleId IdType="pii">bmjopen-2023-075741</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med. 1993;14:615&#x2013;31. doi: 10.1016/0891-5849(93)90143-i.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0891-5849(93)90143-i</ArticleId><ArticleId IdType="pubmed">8325534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966;275:457&#x2013;64. doi: 10.1056/NEJM196609012750902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM196609012750902</ArticleId><ArticleId IdType="pubmed">5917940</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015;31 Suppl 2:9&#x2013;14. doi: 10.1185/03007995.2015.1087980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2015.1087980</ArticleId><ArticleId IdType="pubmed">26414731</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi C, Domienik-Kar&#x142;owicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28:1&#x2013;14. doi: 10.5603/CJ.a2021.0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2021.0001</ArticleId><ArticleId IdType="pmc">PMC8105060</ArticleId><ArticleId IdType="pubmed">33438180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombelli M, Ronchi I, Volpe M, et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. J Hypertens. 2014;32:1237&#x2013;44. doi: 10.1097/HJH.0000000000000161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000000161</ArticleId><ArticleId IdType="pubmed">24675682</ArticleId></ArticleIdList></Reference><Reference><Citation>Stack AG, Hanley A, Casserly LF, et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM. 2013;106:647&#x2013;58. doi: 10.1093/qjmed/hct083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hct083</ArticleId><ArticleId IdType="pubmed">23564632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (precis) database cohort study. Arthritis Rheum. 2008;58:623&#x2013;30. doi: 10.1002/art.23121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23121</ArticleId><ArticleId IdType="pubmed">18240236</ArticleId></ArticleIdList></Reference><Reference><Citation>MacIsaac RL, Salatzki J, Higgins P, et al. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension. 2016;67:535&#x2013;40. doi: 10.1161/HYPERTENSIONAHA.115.06344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.115.06344</ArticleId><ArticleId IdType="pubmed">26865199</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertensionthe task force for the management of arterial hypertension of the european society of cardiology (ESC) and the european society of hypertension (ESH) Eur Heart J. 2018;39:3021&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic HEART disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:1195&#x2013;205. doi: 10.1016/S0140-6736(22)01657-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01657-9</ArticleId><ArticleId IdType="pubmed">36216006</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic HEART disease: protocol of the ALL-HEART study. BMJ Open. 2016;6:e013774. doi: 10.1136/bmjopen-2016-013774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-013774</ArticleId><ArticleId IdType="pmc">PMC5020706</ArticleId><ArticleId IdType="pubmed">27609859</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni A, Shahidi S, Seirafian S, et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis. 2010;4:128&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20404423</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacher P, Nivorozhkin A, Szab&#xf3; C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev . 2006;58:87&#x2013;114. doi: 10.1124/pr.58.1.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.58.1.6</ArticleId><ArticleId IdType="pmc">PMC2233605</ArticleId><ArticleId IdType="pubmed">16507884</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Mackenzie IS, Chen Y, et al. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71:600&#x2013;7. doi: 10.1111/j.1365-2125.2010.03887.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2010.03887.x</ArticleId><ArticleId IdType="pmc">PMC3080649</ArticleId><ArticleId IdType="pubmed">21395653</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A-W, Tetzlaff JM, G&#xf8;tzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227&#x2013;337. doi: 10.1093/eurheartj/ehab484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab484</ArticleId><ArticleId IdType="pubmed">34458905</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A. Categorical data analysis. Wiley. 2002;2002 doi: 10.1002/0471249688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471249688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>